COVID-19 numbers speak
for themselves

656,739

Hospitalizations3*

58,502

Deaths4*

112,302

Intensive Care Unit Admissions5

*From Oct. 7, 2023, through September 8, 2024; hospitalizations calculated based on 334.9 million US Census Bureau estimate of US population size and CDC reported rates of hospitalizations

Millions need more protection against COVID-196

Immunocompromised people may be more vulnerable to COVID-19, because they may have a weaker response to COVID-19 vaccines. Immunocompromised people are also at increased risk of severe COVID-19-related illness and death.7

Practice These Prevention Strategies8,9

Encourage practicing extra precautions

Encourage practicing extra precautions

Help reduce the spread of COVID-19

Help reduce the spread of COVID-19

Stay up to date with COVID-19 vaccination

Stay up to date with COVID-19 vaccination

Learn about multilayer protection

Learn about multilayer protection

Arrow Divider
Arrow Divider

Millions need more protection against COVID-196

Immunocompromised people may be more vulnerable to COVID-19, because they may have a weaker response to COVID-19 vaccines. Immunocompromised people are also at increased risk of severe COVID-19-related illness and death.7

Practice These Prevention Strategies8,9

Encourage practicing extra precautions

Encourage practicing extra precautions

Help reduce the spread of COVID-19

Help reduce the spread of COVID-19

Stay up to date with COVID-19 vaccination

Stay up to date with COVID-19 vaccination

Learn about multilayer protection

Learn about multilayer protection

Arrow Divider
Arrow Divider

Understand Layering Protection

A multilayered approach can be just what immunocompromised people need.

The CDC recommends a multilayered approach for immunocompromised people because they’re at increased risk of severe infection. A multilayered approach is exactly what it sounds like–combining multiple paths of protection against COVID-19.1

Exploring a multilayered approach to COVID‑19 prevention in immunocompromised people

The CDC recommends a multilayered approach for immunocompromised people because they’re at increased risk of severe infection. A multilayered approach is exactly what it sounds like–combining multiple paths of protection against COVID-19.1

Exploring a multilayered approach to COVID‑19 prevention in immunocompromised people

uptime
Vaccine

Vaccine10

Yellow Divider

An important layer, but immunocompromised people may have a reduced response.11

Triggers an immune response by teaching the body how to produce SARS-CoV-2 specific antibodies

Primes the body to recognize and fight infections

Can build long-term immunity over time

Monoclonal Antibody

Monoclonal Antibody12,13

Yellow Divider

Adds an extra layer of protection to help boost the immune system's response to COVID-19.14

Molecule designed to mimic or augment the natural immune response

Targets specific viral proteins, inhibiting binding to host cells

May offer immediate protection, yet the duration of potential effectiveness may vary

Arrow Icon
Arrow Icon

Seeking protection
against COVID-19

Immunity to COVID-19 may be achieved through the presence of disease-specific antibodies.15 This immunity can be classified as active, where the body is directly involved in producing protection, or as passive, where protection comes from an external source.

Examples of Active Immunity16

Natural

Active Immunity

A person’s immune system makes antibodies after being exposed to an infection

Artificial

Active Immunity

A person’s immune system makes antibodies after receiving a vaccination

Examples of Passive Immunity16

Natural

Passive Immunity

Comes from the mother, as she transmits antibodies to a baby

Artificial

Passive Immunity

A medicine delivers antibodies to a person’s body

Artificial

Ask Your Doctor

Talking with a doctor is an important first step for immunocompromised people seeking extra protection and to learn about a prescription to help prevent COVID-19.

Learn More

Resources

DownloadDownload Patient Brochure

COVID-19 Resources

CDC: Updated COVID-19 ACIP Vaccination Recommendations

CDC: Identifying People with Immunocompromised Status

Links provided lead to external websites and are provided as a courtesy for informational purposes only.

References

ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; TNF, tumor necrosis factor

  1. COVID-19 can surge throughout the year | NCIRD | CDC
  2. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 — COVID-NET, 10 states, March 2020–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878-884
  3. CDC: COVID Data Tracker. Accessed October 14, 2024. https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitaliztion-network
  4. CDC. COVID Data Tracker. Accessed October 14, 2024. https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00
  5. CDC. COVID Data Tracker. Accessed October 14, 2024. https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalization-network
  6. Prevalence of Immunosuppression Among US Adults. Accessed September 25, 2024. https://jamanetwork.com/journals/jama/fullarticle/2815274#google_vignette
  7. Centers for Disease Control and Prevention. COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised. Accessed September 17, 2034. https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
  8. US Centers for Medicare & Medicaid Services. COVID-19 monoclonal antibodies. Accessed November 30, 2023. https://www.cms.gov/monoclonal
  9. Centers for Disease Control and Prevention. People who are immunocompromised. Accessed November 30, 2023. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html
  10. Centers for Disease Control and Prevention. Understanding how vaccines work. Accessed March 8, 2024. https://www.cdc.gov/vaccines/hcp/conversations/understanding-vacc-work.html
  11. Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. Lancet Rheumatol. 2023;5:e461-e473.
  12. Chary M, Barbuto AF, Izadmehr S, Tarsillo M, Fleischer E, Burns MM. COVID-19 Therapeutics: use, mechanism of action, and toxicity (vaccines, monoclonal antibodies, and immunotherapeutics). J Med Toxicol. 2023;19(2):205-218.
  13. Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021;325(10):1015.
  14. Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. Accessed September 20, 2024. https://pubmed.ncbi.nlm.nih.gov/37400053/
  15. The Role and Uses of Antibodies in COVID-19 Infections: A Living Review. Accessed September 19, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928637/
  16. Centers for Disease Control and Prevention. immunity types. Accessed March 8, 2024. https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm